查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1914506

心臟靶向胜肽市场（按产品类型、递送系统、分子类型、应用和最终用户划分）—全球预测，2026-2032年

Cardiac Targeting Peptides Market by Product Type, Delivery System, Molecule Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年心臟标靶胜肽市场价值为 2.488 亿美元，预计到 2026 年将成长至 2.6304 亿美元，复合年增长率为 4.57%，到 2032 年将达到 3.4027 亿美元。

关键市场统计数据
基准年 2025 2.488亿美元
预计年份：2026年 2.6304亿美元
预测年份 2032 3.4027亿美元
复合年增长率 (%) 4.57%

全面介绍心臟标靶胜肽：科学基础、临床需求与转化挑战如何影响专案开发

心臟标靶胜肽旨在透过整合胜肽化学、分子影像学和标靶治疗，解决心血管疾病诊断和治疗中长期存在的挑战。这些分子被设计成能够选择性地结合心臟组织或疾病特异性生物标记物，从而实现精准成像、标靶药物递送或诊断和治疗的双重功能。人口结构的变化和慢性疾病负担的日益加重，促使临床医生对那些与传统小分子化合物和全身性生技药品相比，具有更高特异性和更低脱靶效应的治疗方式产生了浓厚的兴趣。

新兴的产业趋势揭示了多功能胜肽结构、先进的递送系统和运算设计如何重塑转化研究路径。

在技​​术创新和不断变化的临床需求的驱动下，心血管胜肽领域正经历着变革性的转变。其中最显着的是多功能构建体的兴起，模糊了诊断和治疗之间的界线。能够同时递送影像造影造影和治疗药物的製剂正从概念验证研究阶段迈向早期转化评估阶段。这种整合使得标靶结合和动态的即时评估成为可能，从而缩短了研发週期并促进了适应性研究设计的发展。

分析2025年关税变化如何影响胜肽和辅料的采购、生产决策、临床试验时间表以及策略供应链的韧性

2025年实施的新关税给支持胜肽合成和药物製剂的全球供应链带来了巨大压力。关键原料，例如特殊胺基酸、保护试剂和偶联连接剂，都受到国际贸易的影响，而关税的提高增加了到岸成本，并使研发人员和契约製造的筹资策略变得更加复杂。因此，依赖单一供应商或跨境组件组装的企业即时感受到成本和进度的影响，迫使它们迅速重新谈判供应合约并重新评估替代原材料。

策略性细分洞察：揭示产品类型、临床用途、最终用户、给药平台和分子结构对研发路径的影响

了解细分市场对于专案优先顺序至关重要，因为产品类型、应用、最终用户、递送系统和分子结构各自存在不同的权衡取舍，这些都会影响开发策略和价值创造。按产品类型划分，诊断胜肽针对生物标记检测和成像进行了最佳化。生物标记检测剂进一步分为生物感测器探针和免疫检测相容的ELISA探针，而成像剂通常设计为MRI造影肽或PET示踪剂，每种都需要不同的放射性核素化学性质和稳定性要求。双功能胜肽结合了成像和治疗功能，包括旨在将药物递送与整合成像功能相结合的结构，以及旨在同时进行成像引导治疗的结构。后者可以显着缩短标靶结合与临床疗效之间的证据差距。治疗胜肽则着重于血管生成、抗凋亡讯号传导和心臟保护等生物学结果。血管新生候选药物通常来自纤维母细胞生长因子或血管内皮生长因子模拟物，抗凋亡方法涉及 Bcl-2调变器或 caspase 抑制剂，而心臟保护策略则针对缺血再灌流伤害和心肌梗塞修復。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势将影响临床试验准入、监管互动和商业化路径。

区域背景至关重要，因为全球各市场的研究强度、管理体制、商业基础设施和报销途径各不相同，这将对研发和上市策略产生重大影响。在美洲，学术医疗中心和专科心臟病诊所的集中分布，以及成熟的创投製药生态系统，加速了转化研究的进程，并促进了临床试验网络的建立。该地区的监管机构已为影像剂和治疗性胜肽类药物建立了核准途径，支付方也越来越接受那些能够展现明确诊断价值或减少后续干预措施的技术。这有可能缩短那些能够产生可靠临床证据的项目的商业性化。

企业能力、伙伴关係模式和智慧财产权策略塑造了胜肽类药物研发领域的竞争优势和转化成功。

在心臟标靶胜肽领域，企业策略的差异体现在核心能力、产品组合重点和资本密集度等。大型製药企业倾向于将胜肽类药物专案整合到其更广泛的心血管业务中，利用内部监管专业知识、成熟的生产网络和全球商业化管道来降低后期研发的风险。中型生物技术公司和专业Start-Ups则通常专注于透过分子设计和製剂创新，开发具有竞争优势的差异化平台技术和针对特定适应症的药物。这些规模小规模的公司通常会优先考虑早期在人体中验证药物的作用机制，然后寻求合作伙伴关係和许可协议，以确保关键性试验和商业化所需的资源。

透过专案优先排序、供应链强化以及监管和商业策略的协调，为经营团队切实可行的建议，帮助他们快速取得成效。

产业领导者应采取双轨策略，兼顾近期诊断和递送技术机会与长期治疗目标。务实地讲，优先发展监管路径清晰的计划，例如成像剂和标靶递送系统，将创造早期检验机会和收入来源，从而支持高风险治疗项目。同时，投资可靠的临床前模型和转化生物标记物，将提高心臟保护和血管生成候选药物展现临床意义讯号的可能性。

本文描述了一种混合方法研究框架，该框架整合了初步访谈、文献综述、专利映射、监管分析和检验，以确保研究结果的可靠性。

本分析所依据的研究结合了定性和定量方法，以确保拥有强有力的、多维度的证据基础。主要研究包括对转化和临床研究人员、生产专家以及商业领袖进行结构化访谈，以收集有关技术挑战和策略决策点的第一手资料。次要研究包括对同侪审查文献、临床试验註册库、专利概况和监管指导文件进行系统性回顾，以检验论点并识别影响研发选择的领先。

简明扼要地总结了科学进展、营运需求和战略重点，这些因素将决定心臟标靶胜肽计画的成功。

总之，心臟标靶胜肽代表着一个多方面的机会领域，它将精准诊断、标靶递送和新型治疗方法连结起来。分子设计、偶联化学和递送平台的技术进步正在汇聚，以克服过去在稳定性、生物分布和靶向特异性方面的局限性。同时，商业性和监管方面的复杂性要求制定周密的策略，以降低研发风险，并向临床医生和支付方证明其价值。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的心臟标靶胜肽市场

  • 诊断胜肽
    • 生物标记检测剂
      • 生物感测器探针
      • ELISA探针
    • 影像剂
      • MRI造影肽
      • 宠物追踪器
  • 双功能胜肽
    • 药物递送成像胜肽
    • 影像治疗胜肽
  • 治疗性胜肽
    • 血管生成胜肽
      • FGF模拟胜肽
      • VEGF模拟胜肽
    • 抗凋亡胜肽
      • Bcl2调节胜肽
      • 半胱天冬酶抑制胜肽
    • 心臟保护胜肽
      • 缺血再灌流伤害肽
      • 心肌梗塞胜肽

9. 按递送系统分類的心臟标靶胜肽市场

  • 脂质体缀合物
    • 传统脂质体
      • 阳离子脂质体
      • 中性脂质体
    • 隐形脂质体
      • 甘露糖修饰的脂质体
      • 聚乙二醇化脂质体
  • 奈米颗粒缀合物
    • 金奈米粒子
      • 棒状金奈米粒子
      • 球形金奈米粒子
    • 脂质奈米颗粒
      • 奈米乳液
      • 固体脂质奈米颗粒
    • 聚合物奈米粒子
      • 几丁聚醣颗粒
      • PLGA奈米颗粒
  • 聚合物共轭物
    • PEG缀合物
      • 支链聚乙二醇缀合物
      • 锁状PE​​G缀合物
    • PLGA缀合物
      • 细颗粒物
      • 奈米颗粒

第十章：以分子类型分類的心臟标靶胜肽市场

  • 环肽
    • 二硫键环化
      • 单二硫化物
      • 多二硫化物
    • 颅尾方向环化
      • 核心回收
      • 侧链环化
  • 基于树状聚合物肽
    • PAMAM树状聚合物
      • 第四代
      • 第五代
    • PPI树状聚合物
      • 第三代
      • 第四代
  • 线性胜肽
    • 长链胜肽
      • 21至50种氨基酸
      • 50种或更多氨基酸
    • 短胜肽
      • 10至20种氨基酸
      • 少于10个氨基酸

第十一章：心臟标靶胜肽市场（按应用领域划分）

  • 诊断影像
    • 磁振造影
      • 钆标记胜肽
      • 氧化铁结合胜肽
    • PET影像
      • 氟-18标记胜肽
      • 镓-68标记胜肽
    • 超音波影像
  • 标靶药物递送
    • 基于水凝胶的递送
      • 可注射水凝胶
      • 热响应性水凝胶
    • 脂质体递送
      • 聚乙二醇化脂质体
      • pH敏感脂质体
    • 奈米颗粒递送
      • 金奈米粒子
      • 棒状金奈米粒子
      • 球形金奈米粒子
      • 氧化铁奈米颗粒
  • 治疗
    • 心律不整控制
    • 心臟衰竭治疗
      • Hfpef治疗胜肽
      • HFref治疗性胜肽
    • 心肌梗塞的治疗
      • 急性心肌梗塞胜肽
      • 慢性心肌梗塞修復肽

第十二章：按最终用户分類的心臟靶向胜肽市场

  • 医院和诊所
    • 心臟诊所
      • 门诊部
      • 手术中心
    • 三级医院
      • 私立医院
      • 公立医院
  • 製药公司
    • 大型製药公司
    • 生技公司
      • 中型生技公司
      • 小规模生技公司
  • 研究所
    • 学术机构
      • 政府研究机构
      • 大学
    • CRO
      • 临床合约研究组织
      • 临床前合约研究组织

13. 各地区心臟标靶胜肽市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：心臟标靶胜肽市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国心臟标靶胜肽市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国心臟标靶胜肽市场

第十七章：中国心臟标靶胜肽市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Acesion Pharma
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Ferring Pharmaceuticals Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-AE420CB1529D

The Cardiac Targeting Peptides Market was valued at USD 248.80 million in 2025 and is projected to grow to USD 263.04 million in 2026, with a CAGR of 4.57%, reaching USD 340.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 248.80 million
Estimated Year [2026] USD 263.04 million
Forecast Year [2032] USD 340.27 million
CAGR (%) 4.57%

A comprehensive introduction to cardiac targeting peptides explaining scientific foundations, clinical imperatives, and translational challenges shaping program development

Cardiac targeting peptides represent a convergence of peptide chemistry, molecular imaging, and targeted therapeutics that seeks to address persistent gaps in the diagnosis and treatment of cardiovascular disease. These molecules are engineered to bind selectively to cardiac tissue or disease-specific biomarkers, enabling precision imaging, focused drug delivery, or combined diagnostic-therapeutic functionality. As demographic shifts and chronic disease burdens intensify, the clinical community is increasingly attracted to modalities that promise higher specificity and fewer off-target effects compared with traditional small molecules or systemic biologics.

Transitioning these constructs from concept to clinic requires alignment across discovery, formulation, manufacturing, and regulatory pathways. Innovations in peptide cyclization, dendrimer scaffolds, and nanoparticle conjugation have broadened the design space, while advances in imaging chemistry and delivery systems have improved in vivo stability and targeting performance. Stakeholders spanning academic researchers, biotech ventures, contract research organizations, and established pharmaceutical groups are all engaging to translate promising preclinical findings into human studies. As a result, strategic choices around molecule type, delivery system, and intended application increasingly determine the feasibility and speed of development.

In the near term, diagnostic imaging and targeted drug delivery applications are driving pragmatic, translational work, because they can leverage existing imaging infrastructure and clinical endpoints. Over the medium term, therapeutic peptides designed for cardioprotection, angiogenesis, and anti-apoptotic effects present compelling biological rationales but demand robust evidence of durable benefit and safety. Given these dynamics, a disciplined, evidence-led approach to target selection, conjugation strategy, and clinical trial design is essential to capture the available clinical and commercial opportunities effectively.

Emerging industry shifts reveal how multifunctional peptide constructs, advanced delivery systems, and computational design are reshaping translational pathways

The cardiovascular peptide landscape is undergoing transformative shifts driven by technical innovation and evolving clinical expectations. The most visible change is the rise of multifunctional constructs that blur the line between diagnostics and therapeutics; agents that simultaneously deliver imaging contrast and therapeutic payloads are moving from proof-of-concept studies to early translational evaluation. This integration enables real-time assessment of target engagement and pharmacodynamics, which in turn can compress development cycles and inform adaptive trial designs.

Concurrently, delivery science has matured sufficiently to permit more reliable targeting in vivo. Liposomal and nanoparticle conjugates, together with polymer-based carriers, have increased circulation time and reduced immunogenicity for peptide cargoes. Advances in PEGylation chemistries, dendrimer architectures, and stimulus-responsive hydrogel matrices have enabled more controlled release profiles and tissue residency, thereby widening clinical applicability. As an outcome, programs that once failed due to rapid clearance or off-target toxicity are being revisited with optimized formulations.

Another key shift is the increased use of computational design and high-throughput screening to accelerate lead identification. Machine learning approaches and structural modeling are being applied to predict binding motifs, stability profiles, and off-target interactions, enabling more rational candidate selection. At the ecosystem level, partnerships between academic groups, specialized biotech firms, and clinical centers are growing more strategic, focused on co-development models and shared manufacturing investments. Collectively, these shifts are creating a more cohesive innovation pathway that links early discovery directly to clinical proof of mechanism and, ultimately, to patient impact.

Analysis of how 2025 tariff changes have reshaped peptide and excipient procurement, manufacturing decisions, clinical timelines, and strategic supply chain resilience

The introduction of new tariff measures in 2025 created material pressure across global supply chains that underpin peptide synthesis and formulation. Key raw materials such as specialty amino acids, protective reagents, and conjugation linkers are subject to international trade flows; increased duties have raised landed costs and complicated procurement strategies for developers and contract manufacturers. As a result, organizations reliant on single-source suppliers or on cross-border component assembly experienced immediate cost and scheduling impacts, necessitating rapid renegotiation of supplier agreements and in some cases requalification of alternative inputs.

Beyond reagents, tariff effects propagated into the supply chain for delivery system components. Import costs for lipid excipients, gold or iron oxide nanoparticles, and specialized polymers have increased, prompting many developers to re-evaluate formulation choices and to accelerate qualification of domestically available substitutes. This re-evaluation has implications for product performance and regulatory submissions, because even minor changes in excipient profiles can require additional comparability studies or bridging data to satisfy regulators.

Clinical development and manufacturing timelines were also affected. Increased component costs have led some small and mid-size firms to delay initiation of pivotal studies or to seek co-development partnerships to share financial burdens. At the same time, larger firms have reassessed their outsourcing strategies, with several favoring increased vertical integration or nearshoring to mitigate tariff exposure. These strategic shifts have implications for capacity planning among contract development and manufacturing organizations, and they are reshaping investment priorities within corporate portfolios.

Finally, the tariffs accelerated conversations about resilience. Companies that invested earlier in supplier diversification, dual sourcing, and inventory buffering demonstrated greater operational continuity. Looking forward, regulatory and payer stakeholders are likely to view supply chain robustness as a component of product reliability, which underscores the need for transparent documentation and contingency planning during development and commercialization.

Strategic segmentation insights revealing how product types, clinical uses, end users, delivery platforms, and molecular architectures influence development pathways

Understanding segmentation is critical for program prioritization because product type, application, end user, delivery system, and molecule architecture each carry distinct tradeoffs that influence development strategy and value creation. Within product typologies, diagnostic peptides can be optimized either for biomarker detection or for imaging; biomarker detection agents split further into biosensor probes and immunoassay-compatible ELISA probes, while imaging agents are typically designed as MRI contrast peptides or PET tracers, each demanding different radionuclide chemistry and stability constraints. Dual function peptides merge imaging and therapeutic capabilities, encompassing constructs tailored to drug delivery with integrated imaging functionality and those designed for simultaneous imaging-guided therapy, which can materially shorten the evidence gap between target engagement and clinical effect. Therapeutic peptides focus on biological outcomes such as angiogenesis, anti-apoptotic signaling, or cardioprotection; angiogenic candidates often derive from fibroblast growth factor or vascular endothelial growth factor mimetics, while anti-apoptotic approaches involve either Bcl-2 modulators or caspase inhibitors and cardioprotective strategies address ischemia-reperfusion injury and myocardial infarction repair.

From an application perspective, the dominant use cases divide into diagnostic imaging, targeted drug delivery, and therapeutic treatment, and each application imposes distinct performance priorities. Diagnostic imaging workstreams differentiate among MRI, PET, and ultrasound modalities; MRI solutions frequently use gadolinium or iron oxide conjugates and emphasize relaxivity and retention, PET approaches rely on radionuclides such as fluorine-18 or gallium-68 and prioritize radiochemical stability, while ultrasound imaging can exploit microbubble-targeted peptides for high-resolution perfusion mapping. Targeted drug delivery spans hydrogel-based systems, liposomal delivery, and nanoparticle platforms; hydrogel approaches range from injectable to thermoresponsive formulations that enable localized depot formation, liposomal strategies include PEGylated and pH-sensitive variants to modulate circulation and release, and nanoparticle options use gold or iron oxide cores with differing shapes and surface chemistries to tune biodistribution. Therapeutic treatment areas such as arrhythmia control, heart failure management and myocardial infarction repair require different dosing paradigms, durability of effect, and safety profiles, with arrhythmia programs typically centered on antiarrhythmic peptides and heart failure approaches distinguishing between HFpEF and HFrEF biology.

End user segmentation further influences product design and commercial pathways because hospitals and clinics, pharmaceutical companies, and research institutes each have distinct procurement drivers and operational constraints. Cardiac specialty clinics and tertiary hospitals require device-compatible workflows, validated imaging protocols, and clear reimbursement rationales, whereas large pharmaceutical companies and biotech firms emphasize scalable manufacturing, regulatory precedent, and out-licensing potential. Research institutes, including both academic centers and contract research organizations, prioritize flexibility and translational capacity to support iterative optimization and early human studies. These different end users shape expected evidence packages, preferred delivery formats, and acceptable cost structures.

Lastly, delivery system and molecule type choices-spanning liposomal, nanoparticle, and polymer conjugates, as well as cyclic, dendrimer-based, and linear peptide architectures-drive both technical feasibility and IP strategy. Liposomal conjugates may be conventional or stealth, and modifications such as mannose targeting or PEGylation can materially alter biodistribution. Nanoparticle conjugates offer a broad set of core materials from gold to lipid- and polymer-based platforms, each with unique manufacturing and regulatory considerations. Polymer conjugates such as PEG and PLGA systems allow for controlled release and size-based targeting, while molecule type decisions-opting for cyclic versus linear constructs or leveraging dendrimer scaffolds-impact protease resistance, receptor binding, and synthetic complexity. Integrating segmentation insights across these axes enables teams to map program risks, prioritize experiments, and align commercial propositions with end user expectations.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine clinical trial access, regulatory engagement, and commercialization pathways

Regional context matters because research intensity, regulatory regimes, commercial infrastructure, and reimbursement pathways vary across global markets and materially affect development and adoption strategies. In the Americas, a concentration of academic medical centers, specialized cardiac clinics, and a mature venture and pharmaceutical ecosystem accelerates translational work and facilitates access to clinical trial networks. Regulatory authorities in this region have well-established pathways for imaging agents and therapeutic peptides, and payers are increasingly receptive to technologies that demonstrate clear diagnostic value or reduce downstream interventions, which can shorten the route to commercial adoption for programs that produce robust clinical evidence.

Across Europe, Middle East & Africa, the landscape is heterogenous but rich in specialized clinical centers and collaborative research networks. Regulatory environments differ across jurisdictions, which means that cross-border development often requires tailored regulatory strategies and additional bridging studies. Reimbursement frameworks in many European markets emphasize health technology assessment and real-world effectiveness, prompting sponsors to plan longitudinal outcome measurements alongside traditional safety and efficacy endpoints. Market access in this combined region therefore benefits from early engagement with health authorities and payers to define value propositions that resonate with national systems.

The Asia-Pacific region combines high innovation capacity in select markets with rapidly expanding clinical trial infrastructure and manufacturing capabilities. Several countries in this region have developed strong peptide synthesis and biologics manufacturing clusters, which can be leveraged to reduce cost and accelerate production scale-up. Regulatory authorities are increasingly harmonizing standards and offering expedited pathways for novel therapies that address unmet needs, making Asia-Pacific an attractive geography both for clinical studies and for strategic manufacturing partnerships. Across all regions, local clinical practice patterns, physician training, and diagnostic infrastructure will influence technology uptake, so global strategies must blend centralized development with region-specific commercialization and evidence generation plans.

How corporate capabilities, partnership models, and intellectual property approaches shape competitive advantage and translational success in peptide development

Company strategies within the cardiac targeting peptide arena are differentiated by core capabilities, portfolio focus, and capital intensity. Large pharmaceutical organizations tend to integrate peptide programs into broader cardiovascular franchises, leveraging internal regulatory expertise, established manufacturing networks, and global commercialization channels to de-risk late-stage development. Mid-sized biotech firms and specialized startups often focus on platform technologies or niche indications where molecular design and formulation innovations can create defensible differentiation. These smaller entities typically prioritize early human proof of mechanism and then pursue partnerships or licensing transactions to secure resources for pivotal studies and commercialization.

Contract research and manufacturing organizations play a pivotal role by providing scalable peptide synthesis, conjugation expertise, and GLP/GMP capabilities that enable companies of all sizes to progress candidates without maintaining full in-house infrastructure. Academic spinouts and research institutes continue to be a rich source of novel targeting motifs and preclinical validation, but translating those discoveries requires careful attention to CMC (chemistry, manufacturing, and controls) planning and regulatory expectations.

Across the competitive landscape, companies are prioritizing strategic partnerships that accelerate translation: co-development agreements that combine imaging expertise with therapeutic know-how, supply agreements that secure critical excipients, and licensing deals that enable regional commercialization. Intellectual property strategies emphasize composition of matter for novel peptides, conjugation chemistries, and delivery platform optimizations. Firms that combine strong translational science with clear go-to-market plans-anticipating reimbursement and clinical workflow integration-are best positioned to convert technical promise into clinical impact and commercial viability.

Actionable recommendations for executives to prioritize programs, strengthen supply chains, and align regulatory and commercial strategies for accelerated impact

Industry leaders should adopt a dual-track strategy that balances near-term diagnostic and delivery opportunities with longer-term therapeutic ambitions. In pragmatic terms, prioritizing projects with clearer regulatory pathways-such as imaging agents and targeted delivery systems-can create early validation events and revenue pathways that support riskier therapeutic programs. Concurrently, investing in robust preclinical models and translational biomarkers will increase the probability that cardioprotective and angiogenic candidates demonstrate clinically meaningful signals.

Leaders must also fortify supply chain resilience by diversifying suppliers, qualifying alternative excipients, and negotiating flexible manufacturing agreements. Nearshoring or strategic stockpiling of critical inputs can blunt the impact of trade volatility. From a technology perspective, allocating resources to delivery system optimization-whether liposomal, nanoparticle, or polymer conjugates-will often yield higher returns than incremental molecule optimization alone, because delivery choices frequently dictate clinical performance and regulatory complexity.

Strategic partnerships are essential: co-development with imaging specialists, licensing collaborations with established cardiovascular franchises, and risk-sharing arrangements with payers or clinical networks can accelerate adoption. Finally, companies should engage early with regulators and payers to define acceptable evidence packages, incorporate patient-centered endpoints, and design clinical programs that demonstrate both short-term diagnostic utility and longer-term therapeutic benefit. Investing in talent, digital platforms for trial efficiency, and adaptive trial designs will further enhance execution capacity and shorten time to clinically meaningful readouts.

Description of the mixed methods research framework integrating primary interviews, literature review, patent mapping, regulatory analysis, and validation to ensure reliable findings

The research that underpins this analysis combined qualitative and quantitative approaches to ensure a robust, triangulated evidence base. Primary research included structured interviews with translational scientists, clinical investigators, manufacturing experts, and commercial leaders to capture first-hand perspectives on technical hurdles and strategic decision points. Secondary research encompassed a systematic review of peer-reviewed literature, clinical trial registries, patent landscapes, and regulatory guidance documents to validate claims and identify precedent pathways that influence development choices.

Analytical methods incorporated technology landscaping to map delivery platforms and molecule architectures, comparative regulatory analysis to highlight jurisdictional differences, and scenario planning to assess the operational impact of supply chain disruptions. Data validation steps included cross-referencing interview inputs with public filings and synthesizing disparate data points to produce coherent, reproducible findings. Where uncertainty remained, sensitivity assessments were performed to characterize the potential range of outcomes and to identify the variables with greatest leverage on program feasibility.

Limitations are acknowledged: evolving clinical data, emergent regulatory guidance, and dynamic trade policies can alter timelines and risk profiles. Therefore, readers are advised to use the insights as a strategic framework that should be complemented by project-specific due diligence and ongoing monitoring of regional regulatory and supply chain developments.

A concise conclusion synthesizing scientific advances, operational imperatives, and strategic priorities that determine success for cardiac targeting peptide programs

In summary, cardiac targeting peptides present a multifaceted opportunity space that links precision diagnostics, targeted delivery, and novel therapeutic modalities. Technical advances in molecular design, conjugation chemistries, and delivery platforms are converging to solve historical limitations around stability, biodistribution, and target specificity. At the same time, commercial and regulatory complexities require deliberate strategies to de-risk development and to demonstrate value to clinicians and payers.

Successful programs will combine rigorous translational science with pragmatic choices about application focus, delivery systems, and regional execution. Diagnostic and dual-function constructs offer a realistic route to early clinical validation, while therapeutic peptides addressing cardioprotection, angiogenesis, and anti-apoptotic pathways represent important but more demanding long-term opportunities. Supply chain resilience and strategic partnerships are non-negotiable operational components, particularly under the pressure of changing trade environments. By aligning scientific ambition with operational discipline and market insight, teams can increase the likelihood that promising molecules become clinically meaningful solutions for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Targeting Peptides Market, by Product Type

  • 8.1. Diagnostics Peptides
    • 8.1.1. Biomarker Detection Agents
      • 8.1.1.1. Biosensor Probes
      • 8.1.1.2. Elisa Probes
    • 8.1.2. Imaging Agents
      • 8.1.2.1. Mri Contrast Peptides
      • 8.1.2.2. Pet Tracers
  • 8.2. Dual Function Peptides
    • 8.2.1. Drug Delivery Imaging Peptides
    • 8.2.2. Imaging Therapy Peptides
  • 8.3. Therapeutic Peptides
    • 8.3.1. Angiogenic Peptides
      • 8.3.1.1. Fgf Mimetic Peptides
      • 8.3.1.2. Vegf Mimetic Peptides
    • 8.3.2. Anti Apoptotic Peptides
      • 8.3.2.1. Bcl2 Modulating Peptides
      • 8.3.2.2. Caspase Inhibitor Peptides
    • 8.3.3. Cardioprotective Peptides
      • 8.3.3.1. Ischemia Reperfusion Injury Peptides
      • 8.3.3.2. Myocardial Infarction Peptides

9. Cardiac Targeting Peptides Market, by Delivery System

  • 9.1. Liposomal Conjugates
    • 9.1.1. Conventional Liposomes
      • 9.1.1.1. Cationic Liposomes
      • 9.1.1.2. Neutral Liposomes
    • 9.1.2. Stealth Liposomes
      • 9.1.2.1. Mannose Modified Liposomes
      • 9.1.2.2. PEGylated Liposomes
  • 9.2. Nanoparticle Conjugates
    • 9.2.1. Gold Nanoparticles
      • 9.2.1.1. Rod Shaped Gold Nanoparticles
      • 9.2.1.2. Spherical Gold Nanoparticles
    • 9.2.2. Lipid Nanoparticles
      • 9.2.2.1. Nanoemulsions
      • 9.2.2.2. Solid Lipid Nanoparticles
    • 9.2.3. Polymer Nanoparticles
      • 9.2.3.1. Chitosan Nanoparticles
      • 9.2.3.2. PLGA Nanoparticles
  • 9.3. Polymer Conjugates
    • 9.3.1. PEG Conjugates
      • 9.3.1.1. Branched PEG Conjugates
      • 9.3.1.2. Linear PEG Conjugates
    • 9.3.2. PLGA Conjugates
      • 9.3.2.1. Microparticles
      • 9.3.2.2. Nanoparticles

10. Cardiac Targeting Peptides Market, by Molecule Type

  • 10.1. Cyclic Peptides
    • 10.1.1. Disulfide Cyclized
      • 10.1.1.1. Mono Disulfide
      • 10.1.1.2. Multi Disulfide
    • 10.1.2. Head To Tail Cyclized
      • 10.1.2.1. Backbone Cyclized
      • 10.1.2.2. Side Chain Cyclized
  • 10.2. Dendrimer Based Peptides
    • 10.2.1. PAMAM Dendrimers
      • 10.2.1.1. Generation 4
      • 10.2.1.2. Generation 5
    • 10.2.2. PPI Dendrimers
      • 10.2.2.1. Generation 3
      • 10.2.2.2. Generation 4
  • 10.3. Linear Peptides
    • 10.3.1. Long Chain Peptides
      • 10.3.1.1. 21 To 50 Amino Acids
      • 10.3.1.2. >50 Amino Acids
    • 10.3.2. Short Chain Peptides
      • 10.3.2.1. 10 To 20 Amino Acids
      • 10.3.2.2. <10 Amino Acids

11. Cardiac Targeting Peptides Market, by Application

  • 11.1. Diagnostic Imaging
    • 11.1.1. Mri Imaging
      • 11.1.1.1. Gadolinium Conjugated Peptides
      • 11.1.1.2. Iron Oxide Conjugated Peptides
    • 11.1.2. PET Imaging
      • 11.1.2.1. Fluorine 18 Labeled Peptides
      • 11.1.2.2. Gallium 68 Labeled Peptides
    • 11.1.3. Ultrasound Imaging
  • 11.2. Targeted Drug Delivery
    • 11.2.1. Hydrogel Based Delivery
      • 11.2.1.1. Injectable Hydrogels
      • 11.2.1.2. Thermoresponsive Hydrogels
    • 11.2.2. Liposomal Delivery
      • 11.2.2.1. PEGylated Liposomes
      • 11.2.2.2. PH Sensitive Liposomes
    • 11.2.3. Nanoparticle Delivery
      • 11.2.3.1. Gold Nanoparticles
      • 11.2.3.1.1. Rod Shaped Gold Nanoparticles
      • 11.2.3.1.2. Spherical Gold Nanoparticles
      • 11.2.3.2. Iron Oxide Nanoparticles
  • 11.3. Therapeutic Treatment
    • 11.3.1. Arrhythmia Control
    • 11.3.2. Heart Failure Treatment
      • 11.3.2.1. Hfpef Treatment Peptides
      • 11.3.2.2. Hfref Treatment Peptides
    • 11.3.3. Myocardial Infarction Management
      • 11.3.3.1. Acute Mi Peptides
      • 11.3.3.2. Chronic Mi Repair Peptides

12. Cardiac Targeting Peptides Market, by End User

  • 12.1. Hospitals And Clinics
    • 12.1.1. Cardiac Specialty Clinics
      • 12.1.1.1. Outpatient Clinics
      • 12.1.1.2. Surgical Centers
    • 12.1.2. Tertiary Care Hospitals
      • 12.1.2.1. Private Hospitals
      • 12.1.2.2. Public Hospitals
  • 12.2. Pharmaceutical Companies
    • 12.2.1. Big Pharma
    • 12.2.2. Biotech Firms
      • 12.2.2.1. Mid Size Biotechs
      • 12.2.2.2. Small Biotechs
  • 12.3. Research Institutes
    • 12.3.1. Academic Institutions
      • 12.3.1.1. Government Labs
      • 12.3.1.2. Universities
    • 12.3.2. CROs
      • 12.3.2.1. Clinical CROs
      • 12.3.2.2. Preclinical CROs

13. Cardiac Targeting Peptides Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiac Targeting Peptides Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiac Targeting Peptides Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiac Targeting Peptides Market

17. China Cardiac Targeting Peptides Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Acesion Pharma
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bristol-Myers Squibb Company
  • 18.9. Eli Lilly and Company
  • 18.10. Ferring Pharmaceuticals Inc.
  • 18.11. Merck KGaA
  • 18.12. Novartis AG
  • 18.13. Novo Nordisk A/S
  • 18.14. Pfizer Inc.
  • 18.15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC TARGETING PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY <10 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY <10 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY <10 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE